Clinical Trial Services
FDA Standard Next Gen
DNA Sequencing
FDA Standard Sequencing
Primer Walking
Shotgun Sequencing
SNP Resequencing
FDA Standard qPCR
FDA Standard Microarray
FDA Standard Microbial ID
Companion Diagnostics
Genetic Stability Testing
Biorepository
Biomarker Discovery
 
Research Services

 
 

SNP Resequencing

Figure: The top pane shows the hetero-indel sequence trace. An AAG indel causes the frameshift. The bottom 3 panes show the deconvoluted peak profiles of the conserved and mutant forms. The deconvoluted profiles can be clearly seen as overlapping peaks in the pane 1 unanalyzed hetero-indel profile. Picture was taken using Mutation Surveyor™ from SoftGenetics.
 

SNP Resequencing

Description of Services

  • Assay development and validation with many pre-validated genes already available.
  • PCR amplification and product purification
  • Bi-directional DNA sequencing on ABI 3730xl DNA sequencers
  • Mutation profiling & sequence variation reporting
  • Geospiza Finch® Suite sample tracking
  • Automated calling & manual curation of heterozygotes
  • Optional 2 assay-platform packages for strong validation of any SNPs
  • ASSAY TESTING AGAINST THE HAP-MAP SAMPLES
  • Experienced with tumor sample and working with parrafin-embedded tissues
  • dbSNP submission available

2-Platform, Mutation-Validation Assay Packages
For highly reliable confirmation of novel SNPs, it is recommended that a second assay-platform be used to validate the mutation. Following mutation discovery by sequencing, the most common secondary method is a SNP genotyping/allelic discrimination assay. SeqWright offers this 2-assay approach as an integrated package for high-confidence data suitable for any publication.

Assay Testing Against the HapMap Samples
If a new mutation has been discovered in a patient panel, a valuable next step approach is to screen the mutation against the HapMap samples, available from the Coriell Institute, for any positive haplotype associations that may contribute to a particular disease or drug response. The HapMap panels are commercially available. SeqWright will provide consultation about which HapMap panel is most appropriate for a particular study and will screen the set for the new mutation.

Tumor Samples & Heterogeneous Mixtures
SeqWright is experienced detecting low-frequency mutations in uneven mixtures, such as tumor samples and pooled DNA, as low as 10% using standard PCR and sequencing. Mixtures with mutations below 10% can be detected using a subcloning strategy.

Heterozygote insertion-deletions (indels) are detected by the frameshift in data and the loss of signal quality at the boundary. Again, the 10% threshold applies. The deconvoluted hetero-indel peak profiles are included in the final report.

  • DNA extraction from paraffin-embedded tissue
  • Detection of low-frequency mutations as low as 10% without subcloning
  • Detection and deconvolution of hetero-indel profiles
  • Whole Genome Amplification (WGA) for low sample quantities
  • CLIA certified for handling patient samples
  • 21 CFR 58 and 21 CFR 11 compliant

    **Not for diagnostic purposes.

DNA Amplification (EBV Transformation and WGA)
Whether limited by very small sample amounts or needing to maintain a perpetual supply of DNA belonging to a specific genotype, SeqWright offers services for both increasing and preserving critical DNA samples for future studies. Methods have been validated for both STR and SNP genotyping.

Additional Resources

  • SNP genotyping on the Affymetrix platform
  • DNA and tissue banking for ongoing studies
  • Contact a sales representative about our services